SecBot SecBot
SECBOTREPLAY Home › Report › RIGL

RIGL · Rigel Pharmaceuticals completed its previously announced exclusive…

RIGEL PHARMACEUTICALS INC · 8-K filed Jun 17, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 17, 2026 at 16:05 ET

Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. The deal closed following HSR clearance, with Rigel paying the $70 million upfront cash consideration. This milestone de-risks the transaction but provides no new financial terms beyond the original announcement.

  • License agreement with Arvinas/Pfizer for VEPPANU (vepdegestrant) became effective on June 11, 2026.
  • Company paid a one-time upfront payment of $70.0 million to the licensors upon closing.
  • HSR waiting period terminated early and all other closing conditions satisfied.
  • Rigel granted exclusive global rights to develop, manufacture and commercialize VEPPANU.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access